medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2014, Número 3

<< Anterior Siguiente >>

Arch Neurocien 2014; 19 (3)


La escala unificada de la enfermedad de Parkinson modificada por la Sociedad de Trastornos del Movimiento (MDS-UPDRS): aplicación clínica e investigación

Rodríguez-Violante M, Cervantes-Arriaga A

Idioma: Español
Referencias bibliográficas: 58
Paginas: 157-163
Archivo PDF: 113.88 Kb.


RESUMEN

La enfermedad de Parkinson se caracteriza por un amplio espectro de síntomas motores y no motores. La evaluación clínica de estos síntomas y signos es indispensable para el correcto tratamiento de la enfermedad. Durante décadas se han utilizado las escalas de estadios de Hoehn-Yahr y la unificada de la enfermedad de Parkinson o UPDRS para fines de evaluación del estado motor del paciente, progresión de la enfermedad y como medida de respuesta al tratamiento sintomático. En la actualidad se cuenta con un instrumento más apropiado como, la Escala Unificada de la enfermedad de Parkinson de la Sociedad de Trastornos del Movimiento o MDS-UPDRS. Esta escala presenta un abordaje más completo e integral de los aspectos clínicos relevantes para la evaluación del paciente, tanto para fines clínicos como de investigación. En el presente trabajo se discuten las características de la MDSUPDRS y se describe brevemente el estado actual de su aplicación y uso en la literatura mundial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurol 2007;68:384-6.

  2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-42.

  3. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;1020-8.

  4. (Fahn S, Elton R, Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M. Eds. Recent developments in Parkinson’s disease, Florham Park, NJ. Macmillan Health Care Information 1987;(2)153- 163:293-304.

  5. Movement disorder society task force on rating scales for Parkinson’s disease. The Unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-50.

  6. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 2007; 22:41-7.

  7. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martínez-Mar tin P, et al. Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23:2129-70.

  8. Martínez-Martín P, Rodriguez-Blazquez C, lvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society- Unified Parkinson’s disease rating scale (MDS-UPDRS). J Neurol 2013; 260:228-36.

  9. Goetz CG. [Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson’s disease]. Rev Neurol (Paris) 2010; 166:1-4.

  10. Buck PO, Trautman H, Clark J. Scales for assessing nonmotor symptom severity changes in Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 2011;17:717-23.

  11. Dibble LE, Cavanaugh JT, Earhart GM, Ellis TD, Ford MP, Foreman KB. Char ting the progression of disability in Parkinson disease: study protocol for a prospective longitudinal cohort study. BMC Neurol 2010;10:110.

  12. Zea-Sevilla MA, Martínez-Mar tin P. Rating scales and questionnaires for assessment of sleep disorders in Parkinson’s disease: what tehy inform about? J Neural Transm 2014; Apr 23. En prensa.

  13. Pal G, Goetz CG. Assessing bradykinesia in parkinsonian disorders. Front Neurol 2013; 4:54.

  14. Rascol O. [UPDRS scale is dead. Long live MDS-UPDRS!]. Rev Neurol (Paris) 2010; 166:5-6.

  15. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale: (MDS-UPDRS). Mov Disord 2010;25:1190-4.

  16. Verbaan D, van Rooden SM, Benit CP, van Zwet EW, Marinus J, van Hilten JJ. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson’s disease. Parkinsonism Relat Disord 2011;17:632-4.

  17. Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson’s disease rating scale scores to Movement Disorder Society-unified Parkinson’s disease rating scale scores. Mov Disord 2012; 27:1239-42.

  18. Goetz CG, Tilley BC, Stebbins GT. Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord 2012; 27:166.

  19. Antonini A, Abbruzzese G, Ferini-Strambi L, Tilley B, Huang J, Stebbins GT, et al. Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale. Neurol Sci 2013; 34:683-7.

  20. Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 2012; 27:79-83.

  21. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez- Blazquez C, Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 2013 Apr 22. En prensa.

  22. Tilley BC, La Pelle NR, Goetz CG, Stebbins GT. Using Cognitive Pretesting in Scale Development for Parkinson’s Disease: The Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Example. J Parkinsons Dis 2014 Mar 10. En prensa.

  23. Parkinson’s disease patients with symptom fluctuations. Int Neurosci 2010;120:523-30.

  24. Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, et al. Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-6.

  25. Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I; LABS-PD investigators. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord 2013

  26. Rodríguez-Violante M, Camacho-Ordoñez A, Cervantes-Arriaga A, González-Latapí P, Velázquez-Osuna S. Factors associated with the quality of life of subjects with Parkinson’s disease and burden on their caregivers. Neurologia 2014 Apr 3. En prensa.

  27. Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014 Mar 28. En prensa.

  28. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Fmedsci PE, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 2014 Mar 24. En prensa.

  29. Giorelli M, Bagnoli J, Consiglio L, Lopane M, Zimatore GB, Zizza D, et al. Do non-motor symptoms in Parkinson’s disease differ from essential tremor before initial diagnosis? A clinical and scintigraphic study. Parkinsonism Relat Disord 2014; 20:17-21.

  30. Skorvanek M, Rosenberger J, Gdovinova Z, Nagyova I, Saeedian RG, Groothof f JW, et al. Apathy in elderly nondemented patients with Parkinson’s disease: clinical determinants and relationship to quality of life. J Geriatr Psychiatry Neurol 2013;26:237-43.

  31. Hall LM, Brauer SG, Horak F, Hodges PW. The effect of Parkinson’s disease and levodopa on adaptation of anticipator y postural adjustments. Neuroscience 2013; 250:483-92.

  32. Chou KL, Taylor JL, Patil PG. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord 2013;19:966-9.

  33. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 2013; 123:2730-6.

  34. Mak MK, Auyeung MM. The mini-BESTest can predict parkinsonian recurrent fallers: a 6-month prospective study. J Rehabil Med 2013; 45:565-71.

  35. Williams AJ, Peterson DS, Earhart GM. Gait coordination in Parkinson disease: effects of step length and cadence manipulations. Gait Posture 2013; 38:340-4.

  36. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80:276-81.

  37. Rose MH, Løkkegaard A, Sonne-Holm S, Jensen BR. Improved clinical status, quality of life, and walking capacity in Parkinson’s disease after body weight-suppor ted highintensity locomotor training. Arch Phys Med Rehabil 2013; 94:687-92.

  38. McNeely ME, Earhart GM. Medication and subthalamic nucleus deep brain stimulation similarly improve balance and complex gait in Parkinson disease. Parkinsonism Relat Disord 2013; 19:86-91.

  39. Duncan RP, Earhart GM. Should One Measure Balance or Gait to Best Predict Falls among People with Parkinson Disease? Parkinsons Dis 2012; 2012:923493.

  40. McNeely ME, Duncan RP, Earhart GM. Medication improves balance and complex gait performance in Parkinson disease. Gait Posture 2012; 36:144-8.

  41. Kapur SS, Stebbins GT, Goetz CG. Vibration therapy for Parkinson’s disease: Charcot’s studies revisited. J Parkinsons Dis 2012; 2:23-7.

  42. Ben Sassi S, Nabli F, Hentati E, Nahdi H, Trabelsi M, Ben Ayed H, et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease. Parkinsonism Relat Disord 2012; 18:243-6.

  43. Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair 2012; 26:132-43.

  44. Schrader C, Capelle HH, Kinfe TM, Blahak C, Bäzner H, Lütjens G, et al. GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia. Neurology 2011; 77:483-8.

  45. Daley DJ, Deane KH, Gray RJ, Clark AB, Pfeil M, Sabanthan K, Worth PF, Myint PK. Adherence therapy improves medication adherence and quality of life in people with Parkinson’s disease: a randomized controlled trial. Int J Clin Pract 2014; Apr 20. En prensa.

  46. Duncan RP, Earhart GM. Measuring participation in individuals with Parkinson disease: relationships with disease severity, quality of life, and mobility. Disabil Rehabil 2011; 33:1440-6.

  47. Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, Alvarez- Sánchez M, Arakaki T, Bergareche-Yarza A, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson’s disease patients. Eur J Neurol 2014; 21:519-24.

  48. Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. The MDSUPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease. Parkinsonism Relat Disord 2013; 19:889-93.

  49. Pagonabarraga J, Soriano-Mas C, Llebaria G, López-Solà M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 2014; 20:290-6.

  50. Llebaria G, Pagonabarraga J, Mar tínez-Corral M, García- Sánchez C, Pascual-Sedano B, Gironell A, Kulisevsky J. Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord 2010;25:2785-91.

  51. Santangelo G, Barone P, Abbruzzese G, Ferini-Strambi L, Antonini A. Validation of the Italian version of Parkinson’s Disease-Cognitive Rating Scale (PD-CRS). Neurol Sci 2014;35:537-44.

  52. Lieberman A, Krishnamurthi N, Dhall R, Santiago A, Moguel- Cobos G, Sadreddin A, et al. A simple question about falls to distinguish balance and gait dif ficulties in Parkinson’s disease. Int J Neurosci 2012; 122:710-5.

  53. Crémers J, Phan Ba R, Delvaux V, Garraux G. Construction and validation of the Dynamic Parkinson Gait Scale (DYPAGS). Parkinsonism Relat Disord 2012; 18:759-64.

  54. Vanbellingen T, Lungu C, Lopez G, Baronti F, Müri R, Hallett M, Bohlhalter S. Short and valid assessment of apraxia in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18:348-50.

  55. Vanbellingen T, Kersten B, Bellion M, Temperli P, Baronti F, Müri R, Bohlhalter S. Impaired finger dexterity in Parkinson’s disease is associated with praxis function. Brain Cogn 2011; 77:48-52.

  56. Stamatakis J, Ambroise J, Crémers J, Sharei H, Delvaux V, Macq B, et al. Finger tapping clinimetric score prediction in Parkinson’s disease using low-cost accelerometers. Comput Intell Neurosci 2013; 2013:717853.

  57. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/ gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord 2013; 28:668-70.

  58. Merello M, Gerschcovich ER, Ballesteros D, Cerquetti D. Correlation between the Movement Disorder Society Unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during Ldopa acute challenge. Parkinsonism Relat Disord 2011;17:705-7.




2020     |     www.medigraphic.com